Lumanity is excited to announce that the PHARMO Institute, a renowned organization dedicated to pharmacoepidemiology, drug safety, and health outcomes, is officially part of the Lumanity family. This strategic integration underscores Lumanity’s unwavering commitment to expanding our real world evidence (RWE) capabilities, providing unparalleled study delivery expertise and access to unique, longitudinal, and clinically rich data assets on a global scale.
The PHARMO Institute brings over 25 years of experience as a leading coordinating center for multi-country studies, including:
- Post-authorization safety and efficacy (PASS, PAES) and drug utilization review (DUR)
- Incidence/prevalence, treatment patterns, and patient pathways
- Comparative effectiveness, including synthetic control arms
- Healthcare resource use and cost of illness research
As one of the founding members of The SIGMA Consortium—an alliance of European Network of Centres for Pharmacoepidemiology & Pharmacovigilance (ENCePP) research centers—PHARMO is pivotal in enhancing the understanding of the safety and effectiveness of medical interventions through rigorous methodological research and coordination of multi-country studies for regulatory authorities and health technology assessment bodies.
Lumanity’s RWE team has been successfully collaborating with the PHARMO Institute for over a year, delivering valuable RWE insights to clients worldwide. Together, we are driven by a shared mission to optimize patient access to therapies, focusing on demonstrating real world safety, effectiveness, and value.
The integration of the PHARMO Institute into Lumanity will enhance our capabilities in several key areas:
- Innovative Solutions: Developing advanced real world data analytics, including validation of surrogacy outcomes, informing clinical development strategies, creating machine-learning classification models to predict diagnosis or severity, and utilizing longitudinal data to evaluate long-latency adverse events.
- Enhanced Data Security: Strengthening industry-leading data security practices to anticipate future needs and ensure the protection of confidential patient information.
- Expedited Data Access: Improving our ability to access data more quickly while ensuring full compliance with General Data Protection Regulation (GDPR) and other local and international data regulations.
- Exceptional Client Experience: Increasing our project capacity, delivering complex projects more efficiently, and enhancing customer service.
- Leveraging Expertise: Offering additional insights and capabilities from across Lumanity’s extensive expertise.
Learn more about the PHARMO Institute’s deep RWE capabilities on their website, pharmo.nl.
